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Objectives We sought to examine the incidence and clinical predictors of new-onset type 2 diabetes mellitus (T2DM) within
3 large randomized trials with atorvastatin.
Background Statin therapy might modestly increase the risk of new-onset T2DM.
Methods We used a standard definition of diabetes and excluded patients with prevalent diabetes at baseline. We identi-
fied baseline predictors of new-onset T2DM and compared the event rates in patients with and without new-
onset T2DM.
Results In the TNT (Treating to New Targets) trial, 351 of 3,798 patients randomized to 80 mg of atorvastatin and 308
of 3,797 randomized to 10 mg developed new-onset T2DM (9.24% vs. 8.11%, adjusted hazard ratio [HR]: 1.10,
95% confidence interval [CI]: 0.94 to 1.29, p  0.226). In the IDEAL (Incremental Decrease in End Points
Through Aggressive Lipid Lowering) trial, 239 of 3,737 patients randomized to atorvastatin 80 mg/day and 208
of 3,724 patients randomized to simvastatin 20 mg/day developed new-onset T2DM (6.40% vs. 5.59%, adjusted
HR: 1.19, 95% CI: 0.98 to 1.43, p  0.072). In the SPARCL (Stroke Prevention by Aggressive Reduction in Cho-
lesterol Levels) trial, new-onset T2DM developed in 166 of 1,905 patients randomized to atorvastatin 80 mg/day
and in 115 of 1,898 patients in the placebo group (8.71% vs. 6.06%, adjusted HR: 1.37, 95% CI: 1.08 to 1.75,
p  0.011). In each of the 3 trials, baseline fasting blood glucose, body mass index, hypertension, and fasting
triglycerides were independent predictors of new-onset T2DM. Across the 3 trials, major cardiovascular events
occurred in 11.3% of patients with and 10.8% of patients without new-onset T2DM (adjusted HR: 1.02, 95% CI:
0.77 to 1.35, p  0.69).
Conclusions High-dose atorvastatin treatment compared with placebo in the SPARCL trial is associated with a slightly in-
creased risk of new-onset T2DM. Baseline fasting glucose level and features of the metabolic syndrome are pre-
dictive of new-onset T2DM across the 3 trials. (J Am Coll Cardiol 2011;57:1535–45) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.047An increased risk of new-onset type 2 diabetes mellitus
(T2DM) has been described with a wide variety of drugs,
including thiazide diuretics (1,2), beta-blockers (1–3), glu-
cocorticoids (4), niacin (5), and protease inhibitors (6). In a
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tween trials, and meta-regression
showed that the risk of developing
diabetes with statins was highest in
trials with older participants but
that neither baseline body mass
index (BMI) nor change in low-
density lipoprotein (LDL) choles-
terol concentrations accounted for
residual variation in risk. However,
other clinical predictors were not
examined, and only 1 of the 13
trials in this analysis involved ator-
vastatin, compared with 6 with
pravastatin and 3 with rosuvastatin.
The purpose of this report is to describe the incidence of
new-onset T2DM in 3 additional large randomized trials:
the TNT (Treating to New Targets) trial (8), in which 80
mg and 10 mg/day of atorvastatin were compared in
patients with stable coronary disease; the IDEAL (Incre-
mental Decrease in End Points Through Aggressive Lipid
Lowering) trial (9), in which atorvastatin 80 mg was
compared with simvastatin 20 mg/day in post-myocardial
infarction (MI) patients; and the SPARCL (Stroke Preven-
tion by Aggressive Reduction in Cholesterol Levels) trial (10),
in which 80 mg/day of atorvastatin was compared with placebo
in patients with a recent stroke or transient ischemic attack.
Within each trial, we examined baseline clinical predictors of
incident diabetes. In addition, we compared the subsequent
event rate after the development of new-onset T2DM with the
event rate for patients who did not develop this complication.
Methods
The study design and main findings of the 3 trials have been
published (8–10). Eligibility criteria for the TNT trial
included an age range of 35 to 75 years, documented
coronary disease, and an LDL cholesterol off therapy
between 3.4 and 6.5 mmol/l (130 to 250 mg/dl), decreasing
to 3.4 mmol/l (130 mg/dl) after an 8-week run-in period
on atorvastatin 10 mg/day. Patients were randomized to 10
mg or 80 mg/day of atorvastatin and followed for a median
of 4.9 years. Patients were eligible for the IDEAL trial if
they were 80 years of age or less, had experienced a definite
MI, and qualified for statin therapy according to their
national guidelines at the time of recruitment. The IDEAL
patients were randomized to atorvastatin 80 mg or simva-
statin 20 mg/day and were followed for a median of 4.8
years. Eligibility criteria for the SPARCL trial included a
stroke or transient ischemic attack 1 to 6 months before
study entry, no known coronary disease, and an LDL
cholesterol of 2.6 to 4.9 mmol/l (100 to 190 mg/dl).
Patients were randomized to placebo or atorvastatin 80
Abbreviations
and Acronyms
BMI  body mass index
CI  confidence interval
HDL  high-density
lipoprotein
HR  hazard ratio
LDL  low-density
lipoprotein
MI  myocardial infarction
T2DM  type 2 diabetes
mellitusmg/day and followed for a median of 4.9 years. dIndividual patient level data were available from each of
the 3 trials and included baseline age; sex; baseline smoking
status; history of hypertension and diabetes; history of
coronary events and coronary interventions; medications;
measurements of heart rate, blood pressure, and BMI; and
baseline laboratory values including fasting plasma glucose,
white blood cell count, and lipid levels.
New-onset T2DM was defined prospectively with the
criteria of the West of Scotland investigators; specifically,
2 post-baseline fasting glucose measurements 7.0
mmol/l (126 mg/dl) and at least 1 post-baseline glucose 2
mmol/l (36 mg/dl) above baseline (11). We also included
patients for whom new-onset T2DM was identified
through adverse event reporting. Patients were excluded if
they were known to have diabetes at baseline, if baseline
fasting glucose was 7.0 mmol/l, if 2 post-baseline
measurements were available, or if the baseline fasting
glucose measurement was missing.
In the TNT trial, 1,771 patients were eliminated from
analysis because of known diabetes or a fasting blood
glucose 7.0 mmol/l at baseline; an additional 635 were
excluded because they had missing baseline measurements
(n  3) or 2 post-randomization measurements (n 
32). Thus, of the original TNT cohort, 7,595 (75.9%) of
0,001 were included in this analysis. In the IDEAL trial,
,427 patients were excluded for known diabetes or a fasting
lood glucose 7.0 mmol/l at baseline, leaving 7,461
83.9%) of the original 8,888 patients available for this
nalysis. In the SPARCL trial, 928 patients were excluded
or known diabetes or a fasting blood glucose 7.0 mmol/l
t baseline, leaving 3,803 (80.4%) of the 4,731 randomized
atients available for this analysis.
tatistical analyses. Similar statistical analyses were per-
ormed for each trial. Comparisons between patient groups
ere based on a 2-sample t test for continuous variables and
isher exact test for categorical variables. Variables that
ere not normally distributed, such as white blood cell
ount and triglycerides, were log transformed. The HRs and
5% CIs for the development of new-onset T2DM were
alculated on the basis of Cox proportional hazard analysis.
ultivariate analyses included a full model with the 17
ariables listed in Tables 1, 2, 3, 4, 5, and 6, a reduced
model with backward elimination of nonsignificant vari-
ables at a p  0.05 except for treatment group, and
exploratory models with use of beta-blockers and treat-
ment group, with and without other variables. For each
trial, the risk of new-onset T2DM was calculated for
quintiles of baseline fasting glucose level. A risk score for
the development of new-onset T2DM was calculated by
allocating a point to each of the following 4 risk factors:
baseline fasting glucose 5.6 mmol/l (100 mg/dl), fast-
ing triglycerides 1.7 mmol/l (150 mg/dl), BMI 30
kg/m2, and a history of hypertension.
Major cardiovascular events in patients with and without
ew-onset T2DM were assessed with an extensive time-
ependent Cox proportional hazard analysis including new-
e
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for univariate analysis and adjusting for treatment group,
age, sex, smoking status, baseline fasting glucose and lipid
levels, BMI, blood pressure, use of statins before baseline,
and use of beta-blocker during screening. All time-
dependent covariate Cox proportional hazard analyses were
based on a time interval of 6 months.
Baseline Characteristics by New-Onset T2DM Status During FollowTable 1 Baseline Characteristics by New-Onset T2DM Status D
Baseline Characteristics
Subjects With
New-Onset T2DM
(n  659)
Age, yrs 60.1 8.6
Sex, male 538 (81.6%)
Current smokers 99 (15.0%)
Hypertension 408 (61.9%)
Fasting glucose, mg/dl 108.0 10.9
BMI, kg/m2 30.65 4.75
WBC, 103/mm3 6.39 1.53
SBP, mm Hg 132.6 17.2
DBP, mm Hg 79.7 9.5
Total cholesterol, mg/dl 178.2 24.0
LDL cholesterol, mg/dl 98.6 17.6
HDL cholesterol, mg/dl 45.2 10.4
Total/HDL cholesterol ratio 4.10 0.91
Triglycerides, mg/dl 158.3 78.9
Use of statins during screening 417 (63.3%)
Use of beta-blockers (before or at baseline) 393 (59.6%)
Treatment with atorvastatin 80 mg 351 (53.3%)
Values are mean  SD or n (%). For white blood cell (WBC) and triglyceride: geometric mean was
to Taylor’s theorem (Let X  WBC or triglyceride, Y  ln(X). Geometric SD  exp (ln [mean of Y]) ·
xact test for categorical variables.
BMI bodymass index; DBP diastolic blood pressure; HDL high-density lipoprotein; HR ha
TNT  Treating to New Targets trial.
Baseline Characteristics by New-Onset T2DM Status During FollowTable 2 Baseline Characteristics by New-Onset T2DM Status D
Baseline Characteristics
Subjects With
New-Onset T2DM
(n  447)
Age, yrs 60.5 8.9
Sex, male 372 (83.2%)
Current smokers 95 (21.3%)
Hypertension 179 (40.0%)
Fasting glucose, mg/dl 107.8 10.8
BMI, kg/m2 28.92 4.33
WBC, 103/mm3 6.81 1.82
SBP, mm Hg 138.8 19.6
DBP, mm Hg 81.8 10.2
Total cholesterol, mg/dl 194.9 38.5
LDL cholesterol, mg/dl 118.8 37.7
HDL cholesterol, mg/dl 42.8 11.0
Total/HDL cholesterol ratio 4.83 1.62
Triglycerides, mg/dl 152.2 85.7
Use of statins during screening 347 (77.6%)
Use of beta-blockers (before or at baseline) 354 (79.2%)
Treatment with atorvastatin 80 mg 239 (53.5%)
Values are mean  SD or n (%). For WBC and triglyceride: geometric mean was calculated as the e
(Let XWBC or triglyceride, Y ln(X). Geometric SD exp (ln [mean of Y]) · (exp[variance of Y] 1
ariables.
IDEAL  Incremental Decrease in End Points Through Aggressive Lipid Lowering trial; other abbreviatiResults
Baseline features. During follow-up, new-onset T2DM
was diagnosed in 659 (8.68%) of 7,595 patients in the TNT
trial, 447 (5.99%) of 7,461 patients in the IDEAL trial, and
281 (7.39%) of 3,803 patients in the SPARCL trial. The
clinical characteristics at baseline of the patients with and
n the TNT TrialFollow-Up in the TNT Trial
Subjects Without
New-Onset T2DM
(n  6,936)
Total
(n  7,595) p Value*
60.7 8.9 60.6 8.9 0.098
5,739 (82.7%) 6,277 (82.7%) 0.484
927 (13.4%) 1,026 (13.5%) 0.233
3,434 (49.5%) 3,840 (50.6%) 0.0001
96.4 10.1 97.4 10.7 0.0001
27.86 4.11 28.10 4.24 0.0001
6.00 1.55 6.03 1.55 0.0001
129.4 16.2 129.7 16.3 0.0001
77.9 9.3 78.1 9.3 0.0001
174.2 23.6 174.5 23.6 0.0001
97.5 17.3 97.6 17.4 0.108
48.2 11.1 48.0 11.1 0.0001
3.75 0.83 3.78 0.84 0.0001
130.5 61.7 132.7 63.7 0.0001
4,318 (62.3%) 4,735 (62.3%) 0.614
3,705 (53.4%) 4,098 (54.0%) 0.0025
3,447 (49.7%) 3,798 (50.0%) 0.087
ted as the exponential of mean value on natural log scale. Geometric SD is calculated according
riance of Y]  1). *The p values are based on 2-sample t test for continuous variables and Fisher
tio; LDL low-density lipoprotein; SBP systolic blood pressure; T2DM type 2 diabetes mellitus;
n the IDEAL TrialFollow-Up in the IDEAL Trial
Subjects Without
New-Onset T2DM
(n  7,014)
Total
(n  7,461) p Value*
61.6 9.6 61.5 9.5 0.012
5,681 (81.0%) 6,053 (81.1%) 0.262
1,495 (21.3%) 1,590 (21.3%) 1.000
2,078 (29.6%) 2,257 (30.3%) 0.0001
97.5 9.8 98.1 10.1 0.0001
26.82 3.55 26.95 3.64 0.0001
6.55 1.85 6.57 1.85 0.0028
136.0 20.0 136.2 20.0 0.0053
80.2 10.2 80.3 10.2 0.0014
196.9 39.0 196.8 39.0 0.281
122.5 34.7 122.3 34.6 0.031
46.9 12.1 46.6 12.1 0.0001
4.47 1.40 4.47 1.42 0.0001
128.7 64.0 130.0 65.5 0.0001
5,309 (75.7%) 5,656 (75.8%) 0.393
5,221 (74.4%) 5,575 (74.7%) 0.025
3,498 (49.9%) 3,737 (50.1%) 0.144
tial of mean value on natural log scale. Geometric SD is calculated according to Taylor’s theorem
p values are based on 2-sample t test for continuous variables and Fisher exact test for categorical-Up iuring
calcula
(exp[va-Up iuring
xponen
). *Theons as in Table 1.
v
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New-Onset Diabetes With Atorvastatin April 5, 2011:1535–45without new-onset T2DM are compared in Table 1 for the
TNT trial, Table 2 for the IDEAL trial, and Table 3 for the
SPARCL trial. A larger proportion of the patients were
women in the SPARCL trial compared with the other 2
trials—41% compared with 20%. Hypertension at base-
line was reported less commonly in the IDEAL trial, in 30%
of the patients compared with 50% in the TNT trial, and
58% in the SPARCL trial, although blood pressure at
Baseline Characteristics by New-Onset T2DM Status During FollowTable 3 Baseline Characteristics by New-Onset T2DM Status D
Baseline Characteristics
Subjects With
New-Onset T2DM
(n  281)
Age, yrs 62.7 10.7
Sex, male 176 (62.6%)
Current smokers 51 (18.2%)
Hypertension 203 (72.2%)
Fasting glucose, mg/dl 103.5 11.9
BMI, kg/m2 29.30 4.75
WBC, 103/mm3 6.31 1.65
SBP, mm Hg 141.5 19.3
DBP, mm Hg 84.1 11.1
Total cholesterol, mg/dl 212.7 27.4
LDL cholesterol, mg/dl 132.2 22.3
HDL cholesterol, mg/dl 46.9 12.5
Total/HDL cholesterol ratio 4.78 1.17
Triglycerides, mg/dl 155.6 78.8
Use of statins during screening 7 (2.5%)
Use of beta-blockers (before or at baseline) 72 (25.6%)
Treatment with atorvastatin 80 mg 166 (59.1%)
Values are mean  SD or n (%). For WBC and triglyceride: geometric mean was calculated as the e
(Let XWBC or triglyceride, Y ln (X). Geometric SD exp (ln [mean of Y]) · (exp[variance of Y] 1
ariables.
SPARCL  Stroke Prevention by Aggressive Reduction in Cholesterol Levels; other abbreviation
Univariate and Multivariate Analyses of Predictors of New-Onset T2Table 4 Univariate and Multivariate Analyses of Predictors of N
Baseline Characteristics
Univariate Analy
HR (95% CI)*
Age, yrs per 5-yr increase 0.97 (0.93–1.01)
Fasting glucose per 10-mg/dl increase 2.76 (2.56–2.97)
BMI per 3-kg/m2 increase 1.28 (1.25–1.32)
Natural log [WBC] per 0.25-log (103/mm3) increase 1.27 (1.18–1.38)
SBP per 20-mm Hg increase 1.24 (1.13–1.36)
DBP per 10-mm Hg increase 1.21 (1.11–1.31)
Total cholesterol per 20-mg/dl increase 1.14 (1.07–1.21)
LDL cholesterol per 10-mg/dl increase 1.032 (0.988–1.078)
HDL cholesterol per 10-mg/dl increase 0.76 (0.70–0.82)
Total/HDL cholesterol ratio per 1-U increase 1.51 (1.40–1.63)
Natural log [triglyceride] per 1.0-log (mg/dl) increase 2.78 (2.33–3.32)
Sex, male 0.94 (0.77–1.15)
Current smokers 1.14 (0.92–1.41)
Hypertension 1.64 (1.40–1.92)
Use of statins during at screening 1.065 (0.91–1.25)
Use of beta-blockers (before or at baseline) 1.28 (1.10–1.50)
Treatment with atorvastatin 80 mg 1.15 (0.98–1.34)*The hazard ratio (HR) along with its corresponding 95% confidence interval (CI) and p values are based
Abbreviations as in Table 1.baseline was as high in the IDEAL trial as in the SPARCL
trial, with measurements in the TNT trial being lower.
Baseline lipid levels among the 3 trials are not directly
comparable, because of differences in prior statin usage; for
example, at baseline all the TNT patients had been taking
atorvastatin 10 mg/day during an 8-week run-in period.
Only 2 patients included in this analysis from the 3 trials
were taking diabetes medication at baseline.
n the SPARCL TrialFollow-Up in the SPARCL Trial
Subjects Without
New-Onset T2DM
(n  3,522)
Total
(n  3,803) p Value*
62.5 11.7 62.5 11.6 0.725
2,069 (58.8%) 2,245 (59.0%) 0.208
694 (19.7%) 745 (19.6%) 0.585
2,019 (57.3%) 2,222 (58.4%) 0.0001
95.2 10.2 95.8 10.5 0.0001
26.98 4.33 27.15 4.40 0.0001
6.04 1.74 6.06 1.74 0.0093
137.7 19.4 137.9 19.5 0.0013
81.5 10.7 81.7 10.7 0.0001
212.6 29.3 212.6 29.1 0.981
133.9 24.0 133.7 23.8 0.267
51.4 14.1 51.0 14.0 0.0001
4.39 1.19 4.42 1.12 0.0001
124.9 60.4 126.9 62.3 0.0001
86 (2.4%) 93 (2.5%) 0.843
602 (17.1%) 674 (17.7%) 0.0006
1,739 (49.4%) 1,905 (50.1%) 0.0019
tial of mean value on natural log scale. Geometric SD is calculated according to Taylor’s theorem
p values are based on 2-sample t test for continuous variables and Fisher exact test for categorical
Table 1.
in the TNT Trialnset T2DM in the TNT Trial
Multivariate Analysis:
Full Model
Multivariate Analysis:
Reduced Model
lue* HR (95% CI)* p Value* HR (95% CI)* p Value*
44 0.98 (0.93–1.03) 0.3804 — —
001 2.53 (2.34–2.73) 0.0001 2.53 (2.34–2.73) 0.0001
001 1.20 (1.15–1.25) 0.0001 1.21 (1.16–1.26) 0.0001
001 1.16 (1.06–1.26) 0.0011 1.15 (1.06–1.24) 0.0012
001 1.072 (0.951–1.210) 0.254 — —
001 1.024 (0.92–1.14) 0.655 — —
001 — — — —
62 — — — —
001 — — — —
001 1.076 (0.96–1.21) 0.228 — —
001 1.67 (1.30–2.16) 0.0001 1.85 (1.53–2.22) 0.0001
45 1.028 (0.82–1.28) 0.809 — —
25 0.83 (0.623–1.10) 0.194 — —
001 1.21 (1.02–1.43) 0.029 1.24 (1.05–1.46) 0.0098
36 1.013 (0.86–1.19) 0.874 — —
018 1.022 (0.87–1.20) 0.789 — —
82 1.10 (0.94–1.29) 0.221 1.10 (0.94–1.29) 0.226-Up iuring
xponen
). *TheDMew-O
sis
p Va
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.5
0.2
0.0
0.4
0.0
0.0on Cox proportional hazard analysis.
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April 5, 2011:1535–45 New-Onset Diabetes With AtorvastatinPredictors of new-onset T2DM. In each of the 3 trials,
patients who developed new-onset T2DM were more
ikely to have hypertension at baseline; to be taking
eta-blockers; and to have higher fasting glucose, BMI,
hite blood cell count, systolic and diastolic blood pressure,
otal cholesterol/high-density lipoprotein (HDL) cholesterol
atio, triglycerides, and lower HDL cholesterol, as shown in
Univariate and Multivariate Analyses of Predictors of New-Onset T2Table 5 Univariate and Multivariate Analyses of Predictors of N
Baseline Characteristics
Univariate Analy
HR (95% CI)*
Age, yrs per 5-yr increase 0.96 (0.92–1.01)
Fasting glucose per 10-mg/dl increase 2.63 (2.40–2.88)
BMI per 3-kg/m2 increase 1.45 (1.37–1.55)
Natural log [WBC] per 0.25-log (103/mm3) increase 1.14 (1.05–1.24)
SBP per 20-mm Hg increase 1.14 (1.04–1.24)
DBP per 10-mm Hg increase 1.14 (1.04–1.25)
Total cholesterol per 20-mg/dl increase 0.98 (0.93–1.02)
LDL cholesterol per 10-mg/dl increase 0.97 (0.94–0.998)
HDL cholesterol per 10-mg/dl increase 0.74 (0.67–0.80)
Total/HDL cholesterol ratio per 1-U increase 1.15 (1.10–1.20)
Natural log [triglyceride] per 1.0-log (mg/dl) increase 2.24 (1.84–2.74)
Sex, male 1.15 (0.90–1.48)
Current smokers vs. never smokers 0.99 (0.79–1.25)
Past smokers vs. never smokers 1.20 (0.988–1.45)
Hypertension 1.60 (1.32–1.93)
Use of statins during screening 1.08 (0.87–1.35)
Use of beta-blockers (before or at baseline) 1.28 (1.02–1.61)
Treatment with atorvastatin 1.16 (0.96–1.40)
*The HR along with its corresponding 95% CI and p values are based on Cox proportional hazard
Abbreviations as in Tables 1, 2, and 4.
Univariate and Multivariate Analyses of Predictors of New-Onset T2Table 6 Univariate and Multivariate Analyses of Predictors of N
Baseline Characteristics
Univariate Analy
HR (95% CI)*
Age, yrs per 5-yr increase 1.02 (0.97–1.07)
Fasting glucose per 10-mg/dl increase 2.13 (1.90–2.38)
BMI per 3-kg/m2 increase 1.30 (1.22–1.38)
Natural log [WBC] per 0.25-log (103/mm3) increase 1.18 (1.06–1.31)
SBP per 20-mm Hg increase 1.20 (1.07–1.34)
DBP per 10-mm Hg increase 1.20 (1.09–1.33)
Total cholesterol per 20-mg/dl increase 1.004 (0.93–1.09)
LDL cholesterol per 10-mg/dl increase 0.97 (0.92–1.02)
HDL cholesterol per 10-mg/dl increase 0.76 (0.69–0.84)
Total/HDL cholesterol ratio per 1-U increase 1.21 (1.14–1.29)
Natural log [triglyceride] per 1.0-log (mg/dl) increase 2.99 (2.34–3.81)
Sex, male 1.13 (0.89–1.44)
Current smokers vs. never smokers 0.97 (0.72–1.32)
Past smokers vs. never smokers 1.26 (0.996–1.59)
Hypertension 1.91 (1.47–2.48)
Use of statins during screening 0.96 (0.45–2.03)
Use of beta-blockers (before or at baseline) 1.62 (1.24–2.11)
Treatment with atorvastatin 1.44 (1.14–1.83)*The HR along with its corresponding 95% CI and p values are based on Cox proportional hazard analysi
Abbreviations as in Tables 1, 3, and 4.Tables 1 to 3. New-onset T2DM patients were younger in the
IDEAL trial (p 0.012), but no age differences were observed
in the TNT or SPARCL trials. Sex and current smoking were
not associated with new-onset T2DM.
Predictors of new-onset T2DM are listed in Table 4 for
the TNT trial, Table 5 for the IDEAL trial, and Table 6 for
the SPARCL trial. Fasting glucose, BMI, fasting triglycer-
in the IDEAL Trialnset T2DM in the IDEAL Trial
Multivariate Analysis:
Full Model
Multivariate Analysis:
Reduced Model
e* HR (95% CI)* p Value* HR (95% CI)* p Value*
7 0.97 (0.92–1.03) 0.298 — —
01 2.49 (2.26–2.75) 0.0001 2.49 (2.26–2.74) 0.0001
01 1.28 (1.20–1.37) 0.0001 1.29 (1.20–1.38) 0.0001
15 1.07 (0.97–1.18) 0.179 — —
62 1.03 (0.90–1.17) 0.697 — —
38 0.97 (0.86–1.10) 0.669 — —
0 — — — —
5 — — — —
01 — — — —
01 1.03 (0.95–1.12) 0.417 — —
01 1.31 (0.996–1.73) 0.054 1.48 (1.19–1.83) 0.0004
7 1.04 (0.80–1.35) 0.800 — —
6 1.07 (0.77–1.50) 0.677 — —
6 1.07 (0.82–1.40) 0.604 — —
01 1.35 (1.09–1.67) 0.0057 1.32 (1.09–1.60) 0.005
7 1.06 (0.83–1.35) 0.650 — —
2 1.06 (0.84–1.33) 0.650 — —
0 1.19 (0.99–1.44) 0.072 1.19 (0.98–1.43) 0.075
s.
in the SPARCL Trialnset T2DM in the SPARCL Trial
Multivariate Analysis:
Full Model
Multivariate Analysis:
Reduced Model
e* HR (95% CI)* p Value* HR (95% CI)* p Value*
8 1.04 (0.97–1.11) 0.264 — —
01 1.92 (1.71–2.16) 0.0001 1.96 (1.74–2.20) 0.0001
01 1.19 (1.11–1.28) 0.0001 1.19 (1.11–1.27) 0.0001
31 1.06 (0.94–1.19) 0.364 — —
19 0.93 (0.78–1.10) 0.380 — —
02 1.13 (0.97–1.31) 0.117 — —
0 — — — —
3 — — — —
01 — — — —
01 0.97 (0.86–1.10) 0.671 — —
01 2.64 (1.83–3.81) 0.0001 2.51 (1.92–3.29) 0.0001
7 1.10 (0.83–1.45) 0.530 — —
3 0.995 (0.68–1.46) 0.980 — —
4 1.09 (0.82–1.46) 0.563 — —
01 1.34 (0.997–1.79) 0.052 1.42 (1.08–1.86) 0.012
3 0.70 (0.33–1.48) 0.346 — —
04 1.14 (0.85–1.52) 0.392 — —
24 1.34 (1.05–1.71) 0.018 1.37 (1.08–1.75) 0.011DMew-O
sis
p Valu
0.10
0.00
0.00
0.00
0.00
0.00
0.30
0.03
0.00
0.00
0.00
0.25
0.95
0.06
0.00
0.49
0.03
0.12DMew-O
sis
p Valu
0.52
0.00
0.00
0.00
0.00
0.00
0.92
0.27
0.00
0.00
0.00
0.32
0.85
0.05
0.00
0.91
0.00
0.00s.
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New-Onset Diabetes With Atorvastatin April 5, 2011:1535–45ides, and hypertension were strong predictors by multivar-
iate analysis in all 3 trials. Use of beta-blockers before or at
baseline was a predictor by univariate analysis but not by
multivariate analysis in any model that included baseline
fasting glucose. Baseline blood pressure and HDL choles-
terol measurements were strong predictors in univariate but
not in multivariate analyses.
Effect of high-dose atorvastatin on new-onset T2DM.
In the TNT trial, a trend toward an increase in new-onset
T2DM for the atorvastatin 80 mg group was observed (HR:
1.15, 95% CI: 0.98 to 1.34, p  0.082; and HR: 1.10, 95%
CI: 0.94 to 1.29, p  0.22, for univariate and multivariate
analyses, respectively). Similarly, in the IDEAL trial a trend
toward an increase in new-onset T2DM was observed in the
atorvastatin 80 mg group (HR: 1.16, 95% CI: 0.96 to 1.40,
p  0.12; and HR: 1.19, 95% CI: 0.99 to 1.44, p  0.072,
or univariate and multivariate analyses, respectively). The
omparator treatment groups in these trials were atorvasta-
in 10 mg in the TNT trial and simvastatin 20 mg in the
DEAL trial. In the SPARCL trial, where the comparator
roup was placebo, the incidence of new-onset T2DM was
igher in the atorvastatin 80 mg group (HR: 1.44, 95% CI:
.14 to 1.83, p  0.0024; and HR: 1.34, 95% CI: 1.05 to
.71, p  0.018, for univariate and multivariate analyses,
espectively).
The absolute rates of new-onset T2DM were 9.24% and
.11% in the TNT trial in the 80 and 10 mg groups,
espectively; 6.40% and 5.59% in the IDEAL trial in the
torvastatin and simvastatin groups, respectively; and 8.71%
nd 6.06% in the SPARCL trial in the atorvastatin 80 mg
nd placebo groups, respectively.
ffect of baseline fasting glucose on new-onset T2DM.
he strongest predictor of new-onset T2DM in all 3 trials
as fasting glucose at baseline. As shown in Table 7, higher
uintiles of baseline fasting glucose in each trial were
ssociated with higher HRs for developing new-onset
2DM. The glucose ranges in the quintile where the risk
rst became statistically significant were remarkably consis-
ent across the trials: 5.3 to 5.6 mmol/l (95 to 100 mg/dl) in
he TNT trial, 5.3 to 5.6 mmol/l (95 to 100 mg/dl) in the
Risk of New-Onset T2DM According to Quintile of Baseline FastingTable 7 Risk of New-Onset T2DM According to Quintile of Base
Quintile 1 Quintile 2
TNT
Range (mg/dl) 89 89–95
HR (95% CI) (vs. Q1) — 1.14 (0.73–1.79)
p value (vs. Q1) — 0.57
IDEAL
Range (mg/dl) 90 90–95
HR (95% CI) (vs. Q1) — 1.33 (0.77–2.29)
p value (vs. Q1) — 0.30
SPARCL
Range (mg/dl) 88 88–94
HR (95% CI) (vs. Q1) — 1.15 (0.69–1.90)
p value (vs. Q1) — 0.59Abbreviations as in Tables 1, 2, 3, and 4.IDEAL trial, and 5.4 to 5.8 mmol/l (98 to 105 mg/dl) in
the SPARCL trial.
High-risk subgroups for the development of new-onset
T2DM. As shown in Figure 1, the presence of a baseline
fasting glucose 5.6 mmol/l (100 mg/dl), fasting triglycer-
ides 1.7 mmol/l (150 mg/dl), BMI 30 kg/m2, and a
istory of hypertension were each associated with a much
igher risk of new-onset T2DM in each of the 3 trials. The
Rs were remarkably consistent across the trials, ranging
rom 3.49 to 5.78 for fasting glucose, 1.88 to 2.37 for fasting
riglycerides, 2.36 to 2.73 for BMI, and 1.60 to 1.91 for
ypertension (p  0.0001 for all).
Patients were assigned 1 point for each of these 4 risk
actors. As shown in Table 8, in each of the 3 trials the risk
f developing new-onset T2DM increased with an increas-
ng number of risk factors: in the TNT trial, from 1.46%
ith 0 factors to 30.0% with all 4 factors; in the IDEAL
rial, from 1.55% to 24.8%; and in the SPARCL trial, from
.06% to 34.3%.
As depicted in Figure 2, in each trial not only were
atients with none or 1 of the risk factors at low risk for
ew-onset T2DM but the risk was not increased in the
ore aggressive statin treatment group. However, in the
mall number of patients with 3 or all 4 of the risk factors,
he incidence was not only high but was increased by more
ggressive statin therapy.
rognosis of patients with new-onset T2DM. Major
ardiovascular events (cardiovascular death, MI, stroke, or
esuscitated cardiac arrest) occurred in the 3 trials in 157 of
,387 new-onset T2DM patients (11.3%) and in 1,884 of
7,472 patients who did not develop this complication
10.8%). The HRs for these events in new-onset T2DM
atients were 1.03 (95% CI: 0.78 to 1.35, p  0.83) and
.02 (95% CI: 0.77 to 1.35, p  0.69) by univariate and
ultivariate analyses, respectively. Among patients in the
torvastatin 80 mg groups of the 3 trials, major cardiovas-
ular events occurred in 76 of 756 new-onset T2DM
atients (10.1%) and in 867 of 8,684 patients who did not
evelop new-onset T2DM (10.0%). The HRs for these
vents in new-onset T2DM patients were 0.90 (95% CI:
d Glucose in the 3 TrialsFasting Blood Glucose in the 3 Trials
Quintile 3 Quintile 4 Quintile 5
95–100 100–107 107
2.10 (1.39–3.18) 3.68 (2.51–5.40) 13.2 (9.3–18.9)
0.0004 0.0001 0.0001
95–100 100–106 106
2.18 (1.34–3.54) 3.79 (2.36–6.08) 10.4 (6.70–16.0)
0.0018 0.0001 0.0001
94–98 98–105 105
1.22 (0.71–2.09) 1.96 (1.23–3.13) 5.89 (3.88–8.96)
0.47 0.005 0.0001Blooline
1541JACC Vol. 57, No. 14, 2011 Waters et al.
April 5, 2011:1535–45 New-Onset Diabetes With AtorvastatinFigure 1 Incident Diabetes According to Baseline Clinical Predictors
Incident diabetes in (A) the TNT (Treating to New Targets) trial, (B) the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial, and (C) the
SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial according to baseline clinical predictors. BMI  body mass index; HR  hazard ratio.
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New-Onset Diabetes With Atorvastatin April 5, 2011:1535–450.60 to 1.34, p 0.59) and 0.87 (95% CI: 0.58 to 1.30, p
.49) by univariate and multivariate analyses, respectively.
Among patients excluded from this study due to the
resence of diabetes at baseline, major cardiovascular events
ccurred in 832 of 4,761 patients overall (17.5%) and in 358
f 2,359 patients (15.2%) in the atorvastatin 80 mg groups.
iscussion
he main findings of this study are 2-fold. First, the 80-mg
ose of atorvastatin was associated with an increased risk of
ew-onset T2DM compared with placebo in the SPARCL
rial. The absolute difference between the treatment groups
as 2.65% (8.71% vs. 6.06%), and the adjusted HR was 1.34
95% CI: 1.05 to 1.71). This is slightly higher but still
verlaps with the HR of 1.09 (95% CI: 1.02 to 1.17)
eported in the meta-analysis of 13 placebo-controlled statin
rials (7). In the TNT and IDEAL trials, where the
omparator treatment was a lower dose statin, the trends
oward an increase in new-onset T2DM in the 80-mg
torvastatin group were not statistically significant.
The second main finding in our study is that the
evelopment of new-onset T2DM can be predicted by
aseline fasting glucose level and components of the meta-
olic syndrome—specifically higher triglycerides, higher
MI, and hypertension. These predictors were consistent
cross all 3 trials, and combining them into a score allowed
tratification of the risk of new-onset T2DM. Patients with
score of 0 had a risk of 2% or less in each trial, and those
ith 1 risk factor had a risk of 4% to 5% (Table 7). Only
ith 3 or 4 of the risk factors did the risk of new-onset
2DM exceed 10%. With 3 or 4 risk factors, risk also
ncreased in the atorvastatin 80 mg group versus the
omparator treatment group (Fig. 2).
Low HDL cholesterol levels were predictive of new-onset
2DM by univariate but not multivariate analysis. White
lood cell count, a rough marker of inflammation, was a
nivariate predictor in all 3 trials but a multivariate predictor
nly in the TNT trial. Age, sex, and smoking were not
onsistently predictive of new-onset T2DM.
revious studies. The baseline variables that predicted
ew-onset T2DM in these trials were also predictive of
pontaneous (12,13) or drug-related (1,3,5,14) new-onset
2DM in previous studies. Fasting glucose, blood pressure,
MI, and triglycerides have been associated with spontane-
us new-onset T2DM in patients with hypertension and in
hose with newly acquired impaired fasting glucose (12,13).
n hypertension trials, fasting glucose and BMI have been
he strongest predictors of new-onset T2DM (1,3,14). The
etabolic syndrome has been shown to be a strong predictor
f new-onset T2DM both in clinical trials and in the
eneral population (15–17). These associations are not
urprising, because hyperinsulinemia is both a precursor of
iabetes and an important underlying cause of the metabolicsyndrome.Ri
s T R
R
is
k A
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April 5, 2011:1535–45 New-Onset Diabetes With AtorvastatinFigure 2 Incident Diabetes According to Number of Risk Factors
Incident diabetes in (A) the TNT trial, (B) the IDEAL trial, and (C) the SPARCL trial according to number of risk factors and treatment group. Atorva.  atorvastatin;
ATV10  atorvastatin 10 mg; ATV80  atorvastatin 80 mg; Simva.  simvastatin; other abbreviations as in Figure 1.
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New-Onset Diabetes With Atorvastatin April 5, 2011:1535–45In small studies, atorvastatin has been reported to worsen
glycemic control in Japanese patients (18,19) but not in
Europeans (20,21). At the end of 3.9 years of follow-up in
the CARDS (Collaborative Atorvastatin Diabetes Study) of
2,838 patients with T2DM (22), adjusted mean glycosy-
lated hemoglobin levels were slightly higher, by 0.105%, in
patients randomized to atorvastatin 10 mg/day compared
with placebo (p  0.03).
The mechanism underlying the small increase in new-
onset T2DM in patients treated with statins is unknown.
An increase in cholesterol content of pancreatic beta islet
cells has been reported to decrease insulin secretion (23);
however, statin treatment would be expected to decrease or
have no effect on the cholesterol content of these cells. It is
possible that statins decrease insulin sensitivity in liver or
muscle, but there is no direct experimental evidence to
support this.
Risk/benefit ratio of statins. Cardiovascular risk is as-
sumed to increase with the development of new-onset
T2DM, because patients with diabetes have a higher event
rate than patients without diabetes. For example, in these 3
trials, a major cardiovascular event occurred in 17.5% of the
4,761 patients with diabetes at baseline compared with
10.8% of the 18,859 patients included in this study without
diabetes at baseline. However, the event rate in patients
with new-onset T2DM was much lower than that of
patients with diabetes at baseline and was not appreciably
higher than that of patients without new-onset T2DM
(adjusted HR: 1.02, 95% CI: 0.77 to 1.35).
Although these results do not exclude an increased risk of up
to 35% and an increased risk might become apparent after
longer follow-up, our results suggest that the risk accompany-
ing statin-associated diabetes might not be equivalent to the
usual risk of diabetes. Patients who developed thiazide-induced
new-onset T2DM in the ALLHAT (Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial)
were also not at increased risk of a cardiovascular event (24).
The risk factors for new-onset T2DM shown in this
study are also risk factors for cardiovascular events. Patients
with the metabolic syndrome but without diabetes were at
increased risk in the TNT trial (25), and hypertriglyceride-
mia was a strong predictor of events in the TNT and
IDEAL trials (26). By contrast, patients with these risk
factors also obtained considerable benefit from high-dose
atorvastatin: TNT patients with the metabolic syndrome
without diabetes had an event rate of 11.6% in the 10 mg
group and 8.2% in the 80 mg group (HR: 0.70, 95% CI:
0.57 to 0.84, p  0.0001) (25).
The authors of the recent meta-analysis calculated that
treating 255 patients with a statin for 4 years would induce
1 case of new-onset T2DM but would prevent 5.4 coronary
deaths or MIs for each mmol/l reduction in LDL choles-
terol (7). This benefit would be greater if strokes and
coronary revascularizations were included (7). The benefits
of statin treatment thus far outweigh the risks, particularlybecause it is uncertain as to whether new-onset T2DM itself
increases risk.
Study limitations. The overwhelming majority of patients
enrolled in these 3 trials were Caucasian, and whether the
results are applicable to other populations is unknown.
Some evidence suggests that the risk of statin-associated
new-onset T2DM might be higher in Japanese patients
(18,19). Only 1 of the 3 trials, the SPARCL trial, had a
placebo control group, and in that study the 80-mg/day dose
of atorvastatin was clearly associated with an increased risk
of new-onset T2DM. The trend toward an increased risk in
the atorvastatin 80 mg groups in the TNT and IDEAL
trials, although not statistically significant, suggests that the
incidence might be slightly higher with higher doses or
more potent statins.
The definition of new-onset T2DM used here was the
same definition used in the WOSCOPS (West of Scotland
Coronary Prevention Study) (11) and might be too restric-
tive, because it requires at least 2 elevated post-baseline
fasting glucose measurements. Thus, the absolute incidence
of new-onset T2DM might have been underestimated with
this definition; however, the improved specificity obtained
with stricter criteria for diabetes minimizes bias of the risk
estimate due to misclassification.
Conclusions
The use of high-dose atorvastatin seems to be associated with
a slight increase in the risk of new-onset T2DM, although the
strongest predictors of new-onset T2DM remain baseline
fasting glucose and other features of the metabolic syndrome.
Although any potential increased risk of new-onset T2DM
with atorvastatin might warrant careful monitoring, the bene-
fits of atorvastatin clearly outweigh the risks in patients with
coronary or cerebrovascular disease.
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